ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

A+| A| A-

Needless Encore

progressive members of it which like your own company are seeking to participate in the international search for new and better drugs and which aim to bring the benefits of international research within reach of the Indian medi- cul profession." Is this, one wonders, a threat to withhold supply of new drugs from the Indian market? But perhaps it is an understandable reaction from an industry which used to sell a 250 mg chloramphenicol capsule in this country for well over a rupee in the fifties. Did not the Kefauver Committee of the US Senate report a decade ago that the Indian consumer had financed the entire cost of research on new drugs in the US? Incidentally, it needs to be mentioned in this content that foreign firms have sometimes introduced untried drugs in India and then withdrawn them under pressure from drug control authorities in their own countries. The Indian medical profession, it is to be hoped, has not forgotten that not many years ago a certain US company withdrew an anti- epilepsy drug when tests in the US showed that rats treated with the drug turned blind in six generations 1 That apart, one does not always have to look beyond the seas for tapping the products of research. For instance, the Tariff Commission has pointed out that the cost of Vitamin A manufactured in the country could be brought down by using the process developed by Bengal Immunity. MacKinnon is silent on this point though he is very outspoken about the alleged wrong calculation of the retail price of Glaxo's Vitamin A.

Dear Reader,

To continue reading, become a subscriber.

Explore our attractive subscription offers.

Click here

Back to Top